Cargando…
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters
BACKGROUND: Psoriasis is a chronic inflammatory skin disease that can be successfully treated with a mixture of fumaric acid esters (FAE) formulated as enteric-coated tablets for oral use. These tablets consist of dimethylfumarate (DMF) and salts of monoethylfumarate (MEF) and its main bioactive met...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526253/ https://www.ncbi.nlm.nih.gov/pubmed/15479475 http://dx.doi.org/10.1186/1471-2210-4-22 |
_version_ | 1782121930393911296 |
---|---|
author | Litjens, Nicolle HR van Strijen, Elisabeth van Gulpen, Co Mattie, Herman van Dissel, Jaap T Thio, H Bing Nibbering, Peter H |
author_facet | Litjens, Nicolle HR van Strijen, Elisabeth van Gulpen, Co Mattie, Herman van Dissel, Jaap T Thio, H Bing Nibbering, Peter H |
author_sort | Litjens, Nicolle HR |
collection | PubMed |
description | BACKGROUND: Psoriasis is a chronic inflammatory skin disease that can be successfully treated with a mixture of fumaric acid esters (FAE) formulated as enteric-coated tablets for oral use. These tablets consist of dimethylfumarate (DMF) and salts of monoethylfumarate (MEF) and its main bioactive metabolite is monomethylfumarate (MMF). Little is known about the pharmacokinetics of these FAE. The aim of the present study was to investigate the hydrolysis of DMF to MMF and the stability of MMF, DMF and MEF at in vitro conditions representing different body compartments. RESULTS: DMF is hydrolyzed to MMF in an alkaline environment (pH 8), but not in an acidic environment (pH 1). In these conditions MMF and MEF remained intact during the period of analysis (6 h). Interestingly, DMF was hardly hydrolyzed to MMF in a buffer of pH 7.4, but was rapidly hydrolyzed in human serum having the same pH. Moreover, in whole blood the half-life of DMF was dramatically reduced as compared to serum. The concentrations of MMF and MEF in serum and whole blood decreased with increasing time. These data indicate that the majority of the FAE in the circulation are metabolized by one or more types of blood cells. Additional experiments with purified blood cell fractions resuspended in phosphate buffered saline (pH 7.4) revealed that at concentrations present in whole blood monocytes/lymphocytes, but not granulocytes and erythrocytes, effectively hydrolyzed DMF to MMF. Furthermore, in agreement with the data obtained with the pure components of the tablet, the enteric-coated tablet remained intact at pH 1, but rapidly dissolved at pH 8. CONCLUSION: Together, these in vitro data indicate that hydrolysis of DMF to MMF rapidly occurs at pH 8, resembling that within the small intestines, but not at pH 1 resembling the pH in the stomach. At both pHs MMF and MEF remained intact. These data explain the observation that after oral FAE intake MMF and MEF, but not DMF, can be readily detected in the circulation of human healthy volunteers and psoriasis patients. |
format | Text |
id | pubmed-526253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-5262532004-11-10 In vitro pharmacokinetics of anti-psoriatic fumaric acid esters Litjens, Nicolle HR van Strijen, Elisabeth van Gulpen, Co Mattie, Herman van Dissel, Jaap T Thio, H Bing Nibbering, Peter H BMC Pharmacol Research Article BACKGROUND: Psoriasis is a chronic inflammatory skin disease that can be successfully treated with a mixture of fumaric acid esters (FAE) formulated as enteric-coated tablets for oral use. These tablets consist of dimethylfumarate (DMF) and salts of monoethylfumarate (MEF) and its main bioactive metabolite is monomethylfumarate (MMF). Little is known about the pharmacokinetics of these FAE. The aim of the present study was to investigate the hydrolysis of DMF to MMF and the stability of MMF, DMF and MEF at in vitro conditions representing different body compartments. RESULTS: DMF is hydrolyzed to MMF in an alkaline environment (pH 8), but not in an acidic environment (pH 1). In these conditions MMF and MEF remained intact during the period of analysis (6 h). Interestingly, DMF was hardly hydrolyzed to MMF in a buffer of pH 7.4, but was rapidly hydrolyzed in human serum having the same pH. Moreover, in whole blood the half-life of DMF was dramatically reduced as compared to serum. The concentrations of MMF and MEF in serum and whole blood decreased with increasing time. These data indicate that the majority of the FAE in the circulation are metabolized by one or more types of blood cells. Additional experiments with purified blood cell fractions resuspended in phosphate buffered saline (pH 7.4) revealed that at concentrations present in whole blood monocytes/lymphocytes, but not granulocytes and erythrocytes, effectively hydrolyzed DMF to MMF. Furthermore, in agreement with the data obtained with the pure components of the tablet, the enteric-coated tablet remained intact at pH 1, but rapidly dissolved at pH 8. CONCLUSION: Together, these in vitro data indicate that hydrolysis of DMF to MMF rapidly occurs at pH 8, resembling that within the small intestines, but not at pH 1 resembling the pH in the stomach. At both pHs MMF and MEF remained intact. These data explain the observation that after oral FAE intake MMF and MEF, but not DMF, can be readily detected in the circulation of human healthy volunteers and psoriasis patients. BioMed Central 2004-10-12 /pmc/articles/PMC526253/ /pubmed/15479475 http://dx.doi.org/10.1186/1471-2210-4-22 Text en Copyright © 2004 Litjens et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Litjens, Nicolle HR van Strijen, Elisabeth van Gulpen, Co Mattie, Herman van Dissel, Jaap T Thio, H Bing Nibbering, Peter H In vitro pharmacokinetics of anti-psoriatic fumaric acid esters |
title | In vitro pharmacokinetics of anti-psoriatic fumaric acid esters |
title_full | In vitro pharmacokinetics of anti-psoriatic fumaric acid esters |
title_fullStr | In vitro pharmacokinetics of anti-psoriatic fumaric acid esters |
title_full_unstemmed | In vitro pharmacokinetics of anti-psoriatic fumaric acid esters |
title_short | In vitro pharmacokinetics of anti-psoriatic fumaric acid esters |
title_sort | in vitro pharmacokinetics of anti-psoriatic fumaric acid esters |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526253/ https://www.ncbi.nlm.nih.gov/pubmed/15479475 http://dx.doi.org/10.1186/1471-2210-4-22 |
work_keys_str_mv | AT litjensnicollehr invitropharmacokineticsofantipsoriaticfumaricacidesters AT vanstrijenelisabeth invitropharmacokineticsofantipsoriaticfumaricacidesters AT vangulpenco invitropharmacokineticsofantipsoriaticfumaricacidesters AT mattieherman invitropharmacokineticsofantipsoriaticfumaricacidesters AT vandisseljaapt invitropharmacokineticsofantipsoriaticfumaricacidesters AT thiohbing invitropharmacokineticsofantipsoriaticfumaricacidesters AT nibberingpeterh invitropharmacokineticsofantipsoriaticfumaricacidesters |